InspireMD (NSPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Proposal 2 seeks approval to amend the Certificate of Incorporation to increase authorized common stock from 150 million to 250 million shares.
Proposal 2 is classified as a “routine” matter, allowing brokers to vote uninstructed shares at their discretion under NYSE rules.
Brokers cannot vote uninstructed shares for the Director Election Proposal (Proposal 1) or the Adjournment Proposal (Proposal 4).
Brokers have discretionary authority to vote on the Auditor Reappointment Proposal (Proposal 3) as it is also considered “routine.”
Broker non-votes are counted for quorum but have no effect on the outcome of Proposals 1–4.
Shareholder rights and capital structure
The proposed amendment would increase the number of authorized shares of common stock, potentially impacting future capital raising and shareholder dilution.
Latest events from InspireMD
- Q2 2026 saw flat revenue, a wider net loss, and a major cost-saving workforce reduction amid going concern risks.NSPR
Q2 2026 - Endovascular stenting for carotid disease is accelerating, backed by best-in-class clinical results.NSPR
Bank of America Global Healthcare Conference 2026 - CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market.NSPR
Investor presentation - Q1 revenue up 122% year-over-year; net loss widened and FDA approvals expected to drive growth.NSPR
Q1 2026 - Votes sought for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing - Proxy seeks approval for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing - Innovative stent and CMS changes accelerate a stent-first shift in carotid intervention.NSPR
25th Annual Needham Virtual Healthcare Conference - Q4 revenue up 62% to $3.1M; 2026 outlook strong with up to 65% growth and $54.2M cash.NSPR
Q4 2025 - Net loss widened on higher expenses as FDA approval for CGuard Prime is anticipated in Q3 2025.NSPR
Q1 2025